Latest Media

Warning! Third-party cookies must be enabled to view SlideShare presentations. ×

Having trouble?

Ranbaxy launches generic version of Valtrex in US

Ranbaxy Laboratories Ltd. video

Ranbaxy launches generic version of Valtrex in US


Arun Sawhney, CEO & Managing Director
Mr. Arun Sawhney joined Ranbaxy in May 2008 and was elevated to the position of President-Global Pharmaceutical Business in January 2010. He was appointed as Managing Director of the Company effective August 20, 2010, for a period of three years, and re-designated as CEO & Managing Director effective August 5, 2011. He was re-appointed as CEO & Managing Director of the Company for a period of five years effective January 1, 2012. Mr. Sawhney is an industry veteran, with over three decades of international experience in the Chemical and Pharmaceutical arena. He has held senior functional and management positions in global pharmaceutical companies like Max-Gb, Hindustan Ciba-Geigy, Bayer India Limited and Dr. Reddy’s Laboratories Limited. Mr. Sawhney is one of the founder members of the Pharmaceuticals Export Promotion Council of India (Pharmexcil) and is currently a member of the Advisory Board of the United States Pharmacopeia (USP) in India. He is also the Chairman of the Confederation of Indian Industry (CII)’s National Committee on Pharmaceuticals and a Member of the India-Malaysia CEO Forum, the India-South Africa CEO Forum and the India Africa Business Council constituted by the Government of India. Mr. Sawhney has been Chairman of the Pharmaceutical Committee of the Federation of Indian Chambers of Commerce and Industry (FICCI). He is also a member of the Academic Advisory Council of the International Management Institute (IMI), Delhi, India. An alumnus of IMI, he graduated in Commerce from the Sydenham College of Commerce, Mumbai, India.
Rajiv Gulati, President-Global Pharmaceutical Business
Mr. Rajiv Gulati has over 28 years of experience in the pharmaceutical industry, spanning generic and innovator companies. An MBA, from the Indian Institute of Management, Ahmedabad, India, he also holds an MPharm degree from the Banaras Hindu University, India. He has worked extensively in multicultural global business leadership roles in many countries, including the US, across wide-ranging domains such as business revitalisation; change management; in-licensing/out-licensing of technologies and products; and the creation and implementation of long term strategies. A seasoned professional, Mr. Gulati is adept at managing large business teams across key functions of Marketing, Business Development and Corporate Strategy. He has been associated with the Pharmaceutical Industry as Vice President of the Organisation of Pharmaceutical Producers of India (OPPI); Chair – Pharmaceutical Industry, American Chamber of Commerce (AMCHAM), New Delhi, India; and Advisory Board Member of the National Institute of Pharmaceutical Education and Research (NIPER).
Indrajit Banerjee, President & Chief Financial Officer
Mr. Indrajit Banerjee has rich and varied experience of over 30 years in managing financial operations, across industry sectors, in large organisations. These have included major capital mobilisation; financial structuring and turnaround; investor relations; joint ventures; and improvement of systems, reporting processes and controls, in both established and greenfield projects. As a member of the senior management team, he has played a key role in the growth of the organisations he has been involved with. A seasoned professional, Mr. Banerjee started his career with consulting and audit firm PricewaterhouseCoopers (PwC). Thereafter, he worked with well-known organisations such as the Indian Aluminium Company Limited, Lucent Technologies, Brooke Bond India Limited and Lupin Limited, a company where he gained deep insight into the pharmaceutical industry. Prior to joining Ranbaxy, he was the Chief Financial Officer at Cairn India Limited. A qualified Chartered Accountant, Mr. Banerjee graduated in Commerce from the St. Xavier’s College, Kolkata, India.
Dale Adkisson, Executive VP & Head - Global Quality
Mr. Dale Adkisson brings with him 27 years of rich global experience in quality assurance, quality control, pharmaceutical quality systems and GxP compliance management. He has managed quality and compliance systems for oral solid dosage, sterile products and biologic dosage forms, for both finished products and Active Pharmaceutical Ingredients (APIs). He has worked with multinational pharmaceutical companies such as Novartis, Bristol-Myers Squibb and Daiichi Sankyo. His last assignment, prior to joining Ranbaxy, spanned ten years as Executive Director, Quality Assurance with Daiichi Sankyo, USA. Mr. Adkisson has domain expertise in both the US and European Union quality systems and GxP compliance management standards. He graduated in Biology and Chemistry from Kean University, New Jersey and, thereafter, attended the New Jersey Institute of Technology for graduate studies in Environmental Engineering.
Ashwani Malhotra, Executive VP - Global Pharma Manufacturing & Supply Chain
Mr. Ashwani Malhotra is a seasoned professional with over three decades of experience in the pharmaceutical industry. Prior to joining Ranbaxy, he worked in different capacities and leadership roles in reputed pharma companies such as Warner Hindustan, Cipla and Dr. Reddy’s Laboratories, where he had a successful tenure with oversight of the company’s formulation, technical operations and Supply Chain. Mr. Malhotra joined Ranbaxy in January 2009 and is presently heading the company’s Global Pharma Manufacturing and Supply Chain functions. He is a post-graduate in Pharmacy from the Indian Institute of Technology (BHU), India and has diplomas in Industrial Engineering and Computer Systems and Management.
Ranjan Chakravarti, Head - Transformation & Business Consulting
Mr. Ranjan Chakravarti is a graduate in Science with post-graduation in Business Management. He has 38 years of experience in the global pharmaceutical industry, of which 17 years have been with innovator companies like Boehringer-Knoll, Reckitt & Colman, and Eskayef, and 21 years with leading Indian pharmaceutical companies like Lupin and Ranbaxy. The last 24 years have been in senior leadership roles in India and other countries. He is a seasoned professional and has worked extensively in multicultural environments in functional and management positions across geographies. A veteran of the pharmaceutical industry, he has successfully managed large teams in markets like India and also large businesses spread across geographies. Mr. Chakravarti has been associated with Ranbaxy since 1993 and has handled many responsibilities in areas as varied as Marketing and Sales; Restructuring and Revitalising Businesses; Business Development; Formulation Sourcing and Alliance Management; Acquisition and Divestment projects; and setting up and managing operations in overseas markets. He is a member of the Africa Committee of the Confederation of Indian Industry.
Ranjeev I. Dani, Executive VP & Head-Global Strategy, Corporate and Business Development
Mr. Sanjeev I. Dani joined Ranbaxy in 2001 and rose to become the Regional Director for India. He has played a pivotal role in attaining leadership position for Ranbaxy in India market. Since 2006 as Regional Director, he has been given additional responsibilities for Ranbaxy’s overseas business in the rapidly growing Emerging Markets such as Asia-Pacific, Eastern Europe, CIS, Russia, Africa, Middle East. He is also on the Board of Daiichi-Sankyo Espha, helping to devise a joint strategy for generics in Japan. Mr. Dani is currently the Global Head of Strategy for Ranbaxy. Mr. Dani has nearly 30 years of experience in the global pharmaceutical industry in building branded business across continents for various organisations. Working in different capacities, he has provided leadership to large, culturally diverse teams in companies such as Janssen-Cilag (Johnson & Johnson India), Xian-Janssen (a Johnson & Johnson joint-venture in China), G.D Searle and Lupin. He is a pharmacy graduate and an MBA from Gujarat University, India.
T.L. Easwar, Senior VP-API Manufacturing, Projects & EHS
Mr. T. L. Easwar has nearly three decades of experience in the global pharmaceutical Industry. Prior to joining Ranbaxy, he worked with reputed organisations including Glaxo Smithkline and Sun Pharma. He has domain expertise in critical areas of the manufacturing operations of Bulk Drugs, including Technology Transfer; Engineering and Facilities – Projects; Contract Manufacturing; and Environment, Health & Safety. Mr. Easwar has been the President of the Mohali Industries’ Association and a Board Member in Nimbua Greenfield (Punjab) Ltd. and Ranbaxy Drugs and Chemicals Company. He holds a BTech degree in Chemical Engineering from the Indian Institute of Technology , Kanpur, India.
Sandeep Girotra, Senior VP & Head-Global Human Resources
Mr. Sandeep Girotra is a graduate in Commerce and has done his Master’s in Personnel Management and Industrial Relations from the Tata Institute of Social Sciences, Mumbai. He has over 20 years of rich experience, working in various organisations in India and abroad like SIEL Limited, DuPont India, General Electric and Convergys Corporation. Mr. Girotra has successfully built and led strong teams across various geographies and has considerable knowledge and functional expertise in the core areas of Human Resource Strategy, Leadership Development, Talent Management and Human Resource operations.
Koji Ogawa, Head - Corporate Services
Mr. Koji Ogawa is a veteran in the global pharmaceuticals industry. He has over 29 years of varied experience at Daiichi Sankyo in handling diverse roles and responsibilities that cover business strategy, global leadership & management, organisational planning & development, and global coordination in decision-making & management. In his last assignment with Daiichi Sankyo Inc., USA, he was in charge of global coordination in the areas of executive decision-making and strategic management for the company’s global R&D organisation as well as serving as a senior corporate liaison and a board member of Luitpold Pharmaceuticals Inc., a Daiichi Sankyo group company in New York, USA. Mr. Ogawa, in his current role, spearheads the Hybrid Business, Corporate Communications, Corporate Social Responsibility and Risk Management functions at Ranbaxy. He has a Master’s degree in Business Administration from the Wharton School of the University of Pennsylvania, USA and has completed executive training programmes, including Leadership & Strategy in Pharmaceutical and Biotech at the Harvard Business School and Strategic Management for Pharmaceutical professionals at the Wharton School. Mr. Ogawa holds a Bachelor’s Degree in Business and Commerce from the Keio University, Tokyo, Japan.

News & Analysis

You may also be interested in: